Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 61.90% is 104% above its 5-year average of -1513.38%, near the high end of its 5-year range (-13396.39%–207.62%).
As of the fiscal period ended Tuesday, March 31, 2026. 101.11% above its 12-month average of -5571.90%.
Reported quarterly gross margin; no daily interpolation. Q4 FY2026 (2026-03-31): 61.90%.
GROSS MARGIN
61.90%
GROSS MARGIN AVG TTM
-5571.90%
GROSS MARGIN AVG 3Y
-2405.07%
GROSS MARGIN AVG 5Y
-1513.38%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+101.11%
CURRENT VS 3Y AVG
+102.57%
CURRENT VS 5Y AVG
+104.09%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+49.59%
vs the sector median at left
Virax Biolabs Group Limited
Market Cap
$356454.00
Gross Margin
61.90%
TTM Avg
-5571.90%
3Y Avg
-2405.07%
5Y Avg
-1513.38%
Market Cap
$401484.00
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
2.16%
5Y Avg
0.42%
Market Cap
$481786.00
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$527596.00
Gross Margin
100.00%
TTM Avg
98.27%
3Y Avg
99.13%
5Y Avg
82.75%
Market Cap
$566203.00
Gross Margin
20.00%
TTM Avg
28.69%
3Y Avg
28.89%
5Y Avg
35.93%
Market Cap
$109274.00
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$97282.00
Gross Margin
N/A
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$70949.00
Gross Margin
-4864.71%
TTM Avg
-2432.36%
3Y Avg
-1195.54%
5Y Avg
-797.02%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Virax Biolabs Group Limited (VRAX) | $356454.00 | 61.90% | -5571.90% | -2405.07% | -1513.38% |
| Niki BioSolutions, Inc. (NIKI)vs › | $401484.00 | 0.00% | 0.00% | 2.16% | 0.42% |
| SciSparc Ltd. (SPRC)vs › | $246973.00 | 73.71% | 56.22% | 66.21% | 71.99% |
| XORTX Therapeutics Inc. (XRTX)vs › | $481786.00 | 0.00% | 0.00% | 0.00% | 0.00% |
| VivoSim Labs, Inc. (VIVS)vs › | $527596.00 | 100.00% | 98.27% | 99.13% | 82.75% |
| HCW Biologics Inc. (HCWB)vs › | $566203.00 | 20.00% | 28.69% | 28.89% | 35.93% |
| Silexion Therapeutics Ltd. (SLXN)vs › | $109274.00 | 0.00% | 0.00% | 0.00% | 0.00% |
| Psyence Biomedical Ltd. (PBM)vs › | $97282.00 | N/A | 0.00% | 0.00% | 0.00% |
| PRF Technologies Ltd. (PRFX)vs › | $70949.00 | -4864.71% | -2432.36% | -1195.54% | -797.02% |
| Akanda Corp. (AKAN)vs › | $60340.00 | -60.46% | -17.77% | 23.60% | -269.73% |
Gross Margin
61.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 61.90% |
| 2025-09-30 | -13396.39% |
| 2025-03-31 | -3381.20% |
| 2024-09-30 | -130.71% |
| 2024-03-31 | 50.14% |
| 2023-09-30 | 13.75% |
| 2023-03-31 | -52.95% |
| 2022-09-30 | 2.05% |
| 2022-03-31 | 207.62% |
| 2021-09-30 | 0.00% |
| 2021-03-31 | -21.34% |
| 2020-09-30 | 100.00% |
| 2020-03-31 | 45.81% |
| 2019-09-30 | 45.80% |
